SCHEMBL803931

SCHEMBL803931

CC(N)C(C)(Cc1ccccc1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.52
HIF1A Q16665 1/20 0.52
TRPA1 O75762 1/20 0.47
SLC6A2 P23975 3/20 0.47
TAAR1 Q96RJ0 3/20 0.47
CYP3A4 P08684 4/20 0.46
CYP1A2 P05177 2/20 0.46
RECQL P46063 1/20 0.46
MAPK1 P28482 1/20 0.45
ENPEP Q07075 1/20 0.43
ALPI P09923 1/20 0.43
PKM P14618 1/20 0.43
PTGS1 P23219 1/20 0.43
XIAP P98170 1/20 0.43
SLC7A5 Q01650 1/20 0.43
MAOA P21397 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
CYP2A6 P11509 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3268589 0.85 HIF1A (0.50) SMN1; SMN2HIF1ATRPA1SLC6A2TAAR1
SCHEMBL6982772 0.82 TRPA1 (0.47) SMN1; SMN2HIF1ATRPA1SLC6A2TAAR1
SCHEMBL27479659 0.80 GLA (0.47) SLC6A2SLC6A4SLC6A3LMNA
SCHEMBL7653149 0.79 SMN1; SMN2 (0.56) SMN1; SMN2HIF1ATRPA1SLC6A2TAAR1
SCHEMBL6977671 0.78 CYP3A4 (0.49) SMN1; SMN2HIF1ATRPA1SLC6A2TAAR1
SCHEMBL28972746 0.77 HIF1A (0.46) SMN1; SMN2HIF1ATRPA1SLC6A2TAAR1
Trifluoroacetic Acid SCHEMBL14738207 0.76 SMN1; SMN2 (0.49) SMN1; SMN2HIF1ATRPA1SLC6A2TAAR1
SCHEMBL16447717 0.75 SLC6A2 (0.52) SMN1; SMN2HIF1ATRPA1SLC6A2TAAR1
SCHEMBL31118229 0.75 TRPA1 (0.60) SMN1; SMN2HIF1ATRPA1SLC6A2TAAR1
SCHEMBL11259618 0.75 CYP3A4 (0.73) SMN1; SMN2HIF1ATRPA1SLC6A2TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015021112-A1 DISUBSTITUTED ARYL OXY DERIVATIVES AS SPHINGOSINE-1- PHOSPHATE RECEPTORS MODULATORS ALLERGAN, INC. (US) 2015-02-12 WO disclosed
US-20150045328-A1 DISUBSTITUTED ARYL OXY DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS ALLERGAN, INC. 2015-02-12 US disclosed
US-20120071664-A1 BETA-AMINO ACIDS AND METHODS AND INTERMEDIATES FOR MAKING SAME NDSU RESEARCH FOUNDATION (US) 2012-03-22 US disclosed
US-20120071664-A1 BETA-AMINO ACIDS AND METHODS AND INTERMEDIATES FOR MAKING SAME NDSU RESEARCH FOUNDATION (US) 2012-03-22 US disclosed
US-8034974-B2 Beta-amino acids and methods intermediates for making same NDSU RESEARCH FOUNDATION (US) 2011-10-11 US disclosed
US-8034974-B2 Beta-amino acids and methods intermediates for making same NDSU RESEARCH FOUNDATION (US) 2011-10-11 US disclosed
US-20110218342-A1 BETA-AMINO ACIDS AND METHODS AND INTERMEDIATES FOR MAKING SAME NORTH DAKOTA STATE UNIVERSITY 2011-09-08 US disclosed
US-20110218342-A1 BETA-AMINO ACIDS AND METHODS AND INTERMEDIATES FOR MAKING SAME NORTH DAKOTA STATE UNIVERSITY 2011-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045328-A1 DISUBSTITUTED ARYL OXY DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS S1PR1, S1PR3, S1PR2 SMN1; SMN2 3562/4885HIF1A 2285/4885TRPA1 874/4885
US-20120071664-A1 BETA-AMINO ACIDS AND METHODS AND INTERMEDIATES FOR MAKING SAME BCAT1, BCAT2, DAO SMN1; SMN2 3890/4885HIF1A 1646/4885TRPA1 3992/4885
US-20110218342-A1 BETA-AMINO ACIDS AND METHODS AND INTERMEDIATES FOR MAKING SAME BCAT1, BCAT2, DAO SMN1; SMN2 3890/4885HIF1A 1646/4885TRPA1 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.